Bildkälla: Stockfoto

Oncopeptides Q3 2024: Sluggish Growth - Redeye

Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, but product sales declined. Nevertheless, sales should improve in the next quarters as the Spanish launch gains pace.

Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, but product sales declined. Nevertheless, sales should improve in the next quarters as the Spanish launch gains pace.
Börsvärldens nyhetsbrev
ANNONSER